Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.25.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Operating expenses    
Research and development $ 4,074 $ 984
General and administrative 3,797 775
Total operating expenses 7,871 1,759
Operating loss (7,871) (1,759)
Other (expense) income:    
Interest expense - royalty agreement (1,215) (805)
Fair value adjustments on derivative liabilities - royalty agreement (75) (58)
Interest income, net 752 86
Other income, net 224 0
Loss before income taxes (8,185) (2,536)
Income tax benefit (expense) 0 0
Net loss (8,185) (2,536)
Less: Cumulative Series D preferred dividends 0 (194)
Loss attributable to common stockholders (8,185) (2,730)
Other comprehensive loss:    
Foreign currency translation loss (6) 0
Comprehensive loss $ (8,191) $ (2,730)
Net loss per share of common stock - basic (in dollars per share) $ (0.74) $ (1.54)
Net loss per share of common stock - diluted (in dollars per share) $ (0.74) $ (1.54)
Weighted average common shares outstanding - basic (in shares) 11,013,697 1,770,167
Weighted average common shares outstanding - diluted (in shares) 11,013,697 1,770,167